Table 5.
Neutralization potential of anti-V3 scFvs against a panel of pseudoviruses and primary isolates
| Virus | Clade | 3E6B | 3E7B | scFv (HepB) | 1418 |
|---|---|---|---|---|---|
|
92RW |
A |
45 |
>100 |
>150 |
>150 |
|
SF162 |
B |
115 |
>100 |
>150 |
>150 |
|
QZ4589 |
B |
50 |
>100 |
>150 |
>150 |
|
AIIMS 261 |
C |
110 |
45 |
>150 |
>150 |
|
Du 422 |
C |
>150 |
>100 |
>150 |
>150 |
| ZM 53 | C | >150 | >100 | >150 | >150 |
The cross neutralizing activities of two anti-V3 scFv clones against a panel of subtype-A, B, C viruses that are listed on the left. The numerical values in the table represent the concentration (μg/ml) of scFvs at which 50% neutralization titers (IC50) was reached. AIIMS 261 is the primary isolate generated in our lab from a HIV-1 clade C infected patient. scFv (HepB) is an scFv against the Hepatitis B surface antigen (negative control) and 1418 is human antibody to parvovirus (negative control). Each experiment was performed at least two independent times.